Merck announces results of ZOLINZA® (vorinostat) Phase III and IIb Trials for investigational use for multiple myeloma at American Society of Hematology Annual Meeting
12 December 2011 | By Merck
ZOLINZA in combination with Bortezomib achieved primary endpoint of improved progression-free survival in patients with relapsed and/or refractory multiple myeloma in Phase III trial...